Skip to main content

Lung Transplant; Complications

1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
1
Extended release tacrolimusPhase 31 trial
Active Trials
NCT05001074Unknown145Est. Aug 2024
Abbott
AbbottABBOTT PARK, IL
1 program
Ensure EnliveN/A1 trial
Active Trials
NCT04522388Terminated2Est. Jan 2024
Veloxis Pharmaceuticals
1 program
Tacrolimus Extended Release Oral Tablet [Envarsus]PHASE_11 trial
Active Trials
NCT04469842Recruiting48Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ChiesiExtended release tacrolimus
Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet [Envarsus]
AbbottEnsure Enlive

Clinical Trials (3)

Total enrollment: 195 patients across 3 trials

NCT05001074ChiesiExtended release tacrolimus

Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients

Start: Jul 2020Est. completion: Aug 2024145 patients
Phase 3Unknown
NCT04469842Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet [Envarsus]

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Start: Dec 2023Est. completion: Dec 202648 patients
Phase 1Recruiting
NCT04522388AbbottEnsure Enlive

Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant

Start: Sep 2023Est. completion: Jan 20242 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 195 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.